Fireside Chat Webinar
![](https://imagionbiosystems.com/wp-content/uploads/2022/07/imagion-biosystems-page-header-molecule-trace.png)
Fireside Chat Webinar
Hosted Live | 7 Feb 2023
Bob Proulx, Imagion’s CEO, and Dr. Yalia Jayalakshmi, Chief Development Officer discussed the latest positive independent review of our MagSense® HER2 imaging agent including what this means for Imagion Biosystems; how this accelerates our path to market; an update on the future of our technology; and fielded questions from attendees in a Q&A session.
Questions? Email us: investor@imagionbio.com
Interested to learn more information about our independent review and path to market?
Read More of Our Latest News
Imagion Appoints New Non-Executive Director, Brett Mitchell
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, today announced the appointment of Mr Brett Mitchell
[VIDEO] 2024 Annual General Meeting
Download a copy of the AGM 2024 presentation deck HERE. AGM 2024 Video Transcript: Good morning, ladies and gentlemen. My name is Robert Crew and
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.